We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.41B
AUM Growth
+$274M
Cap. Flow
+$112M
Cap. Flow %
4.66%
Top 10 Hldgs %
24.57%
Holding
158
New
13
Increased
40
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$31.6M
2
TECX
Tectonic Therapeutic
TECX
+$27.9M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$22.5M
4
PANW icon
Palo Alto Networks
PANW
+$20.8M
5
SAGE
Sage Therapeutics
SAGE
+$18.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$52M
2
CAFD
8point3 Energy Partners LP
CAFD
+$18.9M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$18M
4
TWLO icon
Twilio
TWLO
+$12.5M
5
SNA icon
Snap-on
SNA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 42.26%
2 Technology 16.99%
3 Consumer Discretionary 12.15%
4 Industrials 8.07%
5 Utilities 2.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
126
Ventas
VTR
$44.7B
$1.22M 0.05%
21,500
+2,000
+10% +$105K
ARE icon
127
Alexandria Real Estate Equities
ARE
$9.15B
$1.2M 0.05%
+9,500
New +$1.19M
TSRO
128
DELISTED
TESARO, Inc.
TSRO
$1.16M 0.05%
26,000
– –
WELL icon
129
Welltower
WELL
$170B
$1.1M 0.05%
17,600
– –
CWEN icon
130
Clearway Energy Class C
CWEN
$4.94B
$1.05M 0.04%
61,000
– –
PLD icon
131
Prologis
PLD
$136B
$985K 0.04%
+15,000
New +$965K
ERIC icon
132
Ericsson
ERIC
$32.1B
$940K 0.04%
122,500
+7,500
+7% +$54.9K
CIG icon
133
CEMIG Preferred Shares
CIG
$6.21B
$800K 0.03%
853,383
+196,180
+30% +$212K
AYI icon
134
Acuity Brands
AYI
$10.1B
$794K 0.03%
6,850
+2,800
+69% +$341K
LPT
135
DELISTED
Liberty Property Trust
LPT
$776K 0.03%
17,500
+2,000
+13% +$84.7K
LXP icon
136
LXP Industrial Trust
LXP
$3.52B
$698K 0.03%
16,000
– –
TT icon
137
Trane Technologies
TT
$97.3B
$664K 0.03%
+7,400
New +$650K
PSA icon
138
Public Storage
PSA
$59.3B
$454K 0.02%
+2,000
New +$416K
EIGR
139
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$439K 0.02%
1,200
-900
-43% -$320K
FRTX
140
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$345K 0.01%
952
-4,445
-82% -$2.09M
ACRS icon
141
Aclaris Therapeutics
ACRS
$743M
– –
-140,000
Closed -$2.45M
NGNE icon
142
Neurogene
NGNE
$670M
– –
-8,750
Closed -$2.46M
PRTA icon
143
Prothena Corp
PRTA
$440M
– –
-37,000
Closed -$1.36M
TNDM icon
144
Tandem Diabetes Care
TNDM
$1.3B
– –
-275,000
Closed -$1.36M
TSLA icon
145
Tesla
TSLA
$1.22T
– –
-450,000
Closed -$7.98M
TWLO icon
146
Twilio
TWLO
$29B
– –
-327,000
Closed -$12.5M
YARW
147
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
– –
-7
Closed -$940K
FPRX
148
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-105,000
Closed -$1.8M
AKCA
149
DELISTED
Akcea Therapeutics Inc
AKCA
– –
-175,000
Closed -$4.48M
ONCE
150
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-270,000
Closed -$18M
3 4 5
6
7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Eventide Asset Management held 158 positions worth $2.41B, up 13% from $2.14B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management deployed $112M of net new capital in Q2 2018, opening 13 new positions and adding to 40 existing holdings. Its largest new stake was Dianthus Therapeutics: 139,881 shares worth $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Snap-on, an estimated $10.6M trimmed.

  • Eventide Asset Management's largest Q2 2018 buy was Dianthus Therapeutics: 139,881 shares worth $29.5M.
  • Eventide Asset Management added most to Myovant Sciences Ltd. in Q2 2018, an estimated $22.5M increase.
  • Eventide Asset Management's biggest Q2 2018 reduction was Snap-on, cutting an estimated $10.6M.
  • Eventide Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $2.41B portfolio in Q2 2018.
  • Eventide Asset Management opened 13 new positions and closed 14 in Q2 2018.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $2.41B.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.